---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-268075"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:53:12.278078+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Climb Bio Q3 2025 cash $175.8M; pipeline advances with budoprutug and CLYM116 trials

## Summary
- Cash and equivalents $175.8M as of Sep 30, 2025; runway expected through 2027.
- R&D expenses $9.1M (Q3 2025) vs $6.2M (Q3 2024); G&A $5.8M vs $5.5M.
- Phase 2 PrisMN trial of budoprutug initiated; dosing expected in coming weeks.
- CLYM116 Phase 1 trial cleared; first subject dosing expected by year-end 2025.
- New leadership: CFO Susan Altschuller, SVP Tech Ops Adam Villa, SVP People Ashley Jones.

## SEC filing metadata
- accession: 0001193125-25-268075
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312525268075/0001193125-25-268075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312525268075/clym-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-268075
- JSON: https://secwatch.observer/filing/0001193125-25-268075.json
- Plain text: https://secwatch.observer/filing/0001193125-25-268075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.